Abstract: Olanzapine is a widely used atypical antipsychotic with significant weight gain and other metabolic side effects. The locus of the transcription factor 7-like 2 (TCF7L2) gene is strongly associated with type 2 diabetes (T2D). The goal of this study was to determine whether polymorphic TCF7L2 is involved in the susceptibility to the metabolic changes associated with the atypical antipsychotic agents (AAPs). In this study, a parallel clinical study with 3-day consecutive administration of olanzapine (10 mg/day) was conducted in 17 healthy subjects with a genotype of TCF7L2 rs7903146 CC (N = 10) or CT (N = 7). Olanzapine caused rapid metabolic changes including body-weight gain, increased triglycerides level and reduced HDL-cholesterol level in the healthy subjects. rs7093146 T carriers (CT) were found to have greater AUC 0-2 hr of insulin during OGTT compared to those (CC) bearing only reference alleles before and after olanzapine treatment. However, the triglyceride level in the subjects with the CT genotype was found to be significantly lower than that in the subjects with CC genotype. Moreover, a significant interaction between the effect by genotype and that by olanzapine treatment on triglyceride level was identified. Acute olanzapine treatment also significantly caused total protein, albumin and haemoglobin decrease and uric acid increase in the healthy subjects.
Schizophrenia is a serious disorder of the mind and the brain with an estimated incidence of 15 per 100,000 persons in the world [1] that typically begins in late adolescence or early adulthood [2] . The atypical antipsychotic agents (AAPs), including clozapine, olanzapine, risperidone and the more recent ones quetiapine, ziprasidone and aripiprazole, have become the preferred treatment for schizophrenia and schizoaffective disorders [3] . However, compared to other antipsychotics, these drugs, exemplified by olanzapine and clozapine, are associated with more than three times higher incidence of metabolic complications such as weight gain, hyperlipidaemia, impaired glucose tolerance and type 2 diabetes (T2D), which are associated with a significantly increased risk of cardiovascular morbidity and mortality, as well as acute dysregulation of glucose metabolism presenting as diabetic ketoacidosis [4, 5] .
The mechanisms of AAP-associated metabolic derangements remain unclear, and multiple mechanisms have been raised [6] [7] [8] . It has been raised up why AAP-associated metabolic disturbances, like other adverse drug reactions, are only experienced in a fraction of patients. Increasing evidence supports that individual genetic background plays a crucial role in determining AAP-associated metabolic side effects. The concordance among monozygotic twins and high heritability of antipsychotic-induced weight gain suggest a strong genetic component [9] . Recently, variants in multiple genes have been associated with AAP-associated metabolic changes [10] [11] [12] . Although these associations need to be replicated, they suggest that individual predisposition to defects in metabolic homeostasis may contribute to AAP-associated metabolic side effects. Glucose metabolism is critical to maintaining the body's metabolic homeostasis. However, few associations have been made between individual genetic predisposition to glucose metabolism defect and AAP-associated metabolic side effects. In recent years, we have witnessed a leap forward in understanding the genetics of glucose intolerance and its clinical consequence T2D. Approximately 30 genetic loci with common risk variants in human populations are now robustly implicated in T2D susceptibility [13] . It is likely that these identified T2D genetic loci also contribute to metabolic derangements induced by AAPs, an environmental factor of high clinical relevance.
Among the identified T2D genetic loci, transcription factor 7-like 2 (TCF7L2) gene has the strongest effect on T2D aetiology [14] . A variety of single nucleotide polymorphisms (SNPs) in TCF7L2 gene have been associated with the risk of T2D in different ethnic populations [15, 16] . Among them, rs7903146 and rs12255372 are most strongly associated with T2D [17] . TCF7L2, a member of the T-cell-specific high-mobility group (HMG) box-containing family of transcription factors, is a classic effector in canonical morphogenic wingless-type MMTV integration site family (Wnt) signalling pathway. In contrast to the well-studied function of Wnt signalling pathway in tissue or organ development [18] , the role of Wnt signalling in glucose metabolism, obesity and T2D pathogenesis has only recently been recognized [19, 20] . Interestingly, Wnt signalling has been implicated in schizophrenia pathogenesis [21, 22] and antipsychotic drug action [23] . However, it remains unknown whether Wnt signalling and its effector TCF7L2 are also involved in AAP-associated metabolic derangements.
The goal of this study was to determine whether polymorphic TCF7L2 is involved in susceptibility to the metabolic changes associated with AAPs. We characterized the frequencies of two functional TCF7L2 SNPs, rs7903146 and rs12255372, in a healthy Chinese Han population. We further conducted a clinical study to compare the metabolic effects of olanzapine, the most widely used AAP in current clinical treatment, between the subjects carrying rs7903146 (CT or TT) and those carrying only reference alleles (CC). Our results indicated that acute olanzapine treatment could induce significant rapid metabolic changes in healthy subjects, and rs7903146 may confer certain genetic susceptibility to olanzapine-associated metabolic side effects.
Materials and Methods
Participants enrolled for genotyping. The clinical study protocol was approved by the Research Ethics Committee of the Central South University, China. All subjects were provided written and informed consent in compliance with the Code of Ethics of the World Medical Association (Declaration of Helsinki). An unrelated population of healthy volunteers (n = 569, male, age: 22.1 AE 2.0 years) (mean AE S.D.) from mainland China was enrolled in this study for genotyping screening.
Genotyping. A total of 5 mL of venous blood was drawn into a sterile tube containing ethylenediaminetetraacetic acid (EDTA) and stored at À80°C until the isolation of genomic DNA by a standard protocol of chloroform-phenol extraction procedure. There were two primers for polymerase chain reaction and one for pyrosequencing for rs12255372 or rs7903146. An automated pyrosequencing instrument, PyroMarkTM ID (QIAGEN, Hilden, Germany), was used to perform the genotyping. The resulting sequences were analysed automatically by the SNP evaluation software.
Participants enrolled for clinical study. The genomic DNA samples from over 500 healthy Chinese males were genotyped for both TCF7L2 rs7903146 and rs12255372. Forty-three subjects were identified as the heterozygotes of TCF7L2 rs7903146 with the mutant T allele, and no TT homozygotes found from 542 successfully genotyped samples (the genotypes for 5 of 547 samples were not available due to amplification or sequencing failure). Only five subjects were identified as TCF7L2 rs12255372 heterozygotes with the mutant T allele from 547 samples. The frequency of rs12255372 was only 0.5%, and this SNP was not further investigated in the following clinical study. Both TCF7L2 rs7903146 and rs12255372 were in Hardy-Weinberg equilibrium. Ten subjects with the CC genotype and seven subjects with the CT genotype at the locus of TCF7L2 rs7903146 were chosen for the next clinical trial of olanzapine treatment. All of the 17 subjects had a uniform genetic background for GG genotype at locus of TCF7L2 rs12255372 in this prospective study. Written informed consent was obtained from all qualified subjects prior to the beginning of the study. The healthy status of participants was ascertained through medical history, physical examination and routine clinical laboratory tests.
The primary end-point of the study was oral glucose tolerance and insulin levels during OGTT. Secondary end-points were measurements of the blood lipid profile, including triglycerides, total cholesterol and high-and low-density lipoprotein cholesterol. The plasma biochemical levels of uric acid, haemoglobin, total protein and albumin, and bodyweight were also measured as the explorative outcome parameters.
Clinical study flow. As illustrated in fig. 1 , all 17 subjects who were eligible for and had consented to participate in the clinical trial fasted overnight; at 7:00 AM of the next day, the subject's body-weight was recorded and 5 mL of blood was taken from all subjects for basal biochemistry measurements, including total protein, albumin, haemoglobin, triglycerides, total cholesterol, high-density lipoprotein (HDL)-cholesterol, low-density lipoprotein (LDL)-cholesterol and uric acid. The following procedure was defined as oral glucose tolerant test (OGTT): at 8:00 AM, 75 g of glucose was orally administered to all subjects. During the next two hours from 8:00 AM to 10:00 AM, blood was taken from the subjects at 0, 0.5, 1, 1.5 and 2 hr for measurements of glucose and insulin levels in plasma. One week later, the subjects again fasted overnight; at 7:00 AM of the next day, the subject's body-weight was recorded again. At 8:00 PM on the same day, all subjects began to self-administer olanzapine (10 mg/day) over the course of three consecutive evenings. After the three-day course of treatment with olanzapine, the subjects again fasted overnight. On the fourth day, at 7:00 AM, the subjects' body-weight was measured, and 5 mL of blood was taken from all subjects for biochemistry measurements as described above. Immediately after the blood withdrawal, the subjects received the fourth olanzapine (10 mg) at 7:00 AM. One hour later, an experimental OGTT was conducted as described above. The plasma from the blood samples collected during the experimental OGTT was also analysed by high-performance liquid chromatography (HPLC) to determine olanzapine concentrations. The limit of quantification for olanzapine was defined at 0.1 ng/mL. The complete HPLC method is described in the supplemental information.
Statistical analysis. Hardy-Weinberg equilibrium was assessed with a chi-square test of goodness of fit in the DNA samples of studied population. Due to our small sample size, all continuous parameters were log-transformed prior to inferential analysis. Statistical analyses were performed with SPSS (version 11.5 for Windows; SPSS Inc., Chicago, IL, USA). The statistical significance of metabolic changes before versus after olanzapine treatment was tested with a paired ttest. The statistical significance of basal characteristics and metabolic changes by olanzapine between TCF7L2 genotypes and the interaction of TCF7L2 genotypic variation with olanzapine-induced metabolic changes were performed using the independent t-test and two-way analysis of variance (ANOVA; olanzapine 9 genotype), respectively. A two-tailed P-value of <0.05 from analysis of logtransformed data was considered statistically significant. Effect size (ES) was provided and presented as a point estimate of the absolute difference between two quantitative outcome of interests (two genotypes or before and after olanzapine treatment) and the associated 95% confidence interval.
Results

Demographic data of the clinical study participants.
A total of 17 subjects, including 10 with TCF7L2 reference genotypes (CC) and 7 with an rs7903146 mutant allele (CT), consented to participate in the clinical study investigating the effect of TCF7L2 polymorphism on olanzapine-associated metabolic response. All subjects participating in the clinical study had the same genotype at the locus of TCF7L2 rs12255372 (GG). All 17 subjects experienced drowsiness without any other clinical side effects when they were receiving olanzapine (four doses); all subjects completed the entire study. The average age of the participants was 23.0 AE 1.5 years. The body mass index (BMI) (kg/m 2 ) was 19.8 AE 1.9 in the CC group and 20.4 AE 3.0 kg/m 2 in the CT group. The comparison of basal characteristics and anthropometric data between the two TCF7L2 genotypes are shown in table 1. There were no statistical differences between the two genotypes in body-weight, height, diastolic and systolic blood pressure (DBP and SBP), total protein (TP), albumin and haemoglobin (Hb) levels. Surprisingly, the 3-day olanzapine treatment slightly but significantly enhanced body-weight and decreased the total protein, albumin and total haemoglobin (table 1) . However, those characteristics did not show any difference between the two genotypes after olanzapine treatment.
Effects of olanzapine on glucose tolerance and plasma insulin levels in healthy subjects of different TCF7L2 genotypes. We did not detect any effects by the olanzapine treatment on plasma glucose or insulin (stimulated by glucose) concentrations during OGTT in all 17 subjects. With regard to genotype effect on glucose level, we did not observe any difference in glucose level and the area under the glucose concentrationtime curve (AUC) during OGTT either before or after olanzapine administration ( fig. 2A-C) . However, we found that the subjects with the reference genotype (CC) had significantly lower plasma insulin levels at 1.5 and 2.0 hr during the 120 min. OGTT than those with CT did, whether olanzapine was present or not ( fig. 2D, Effects of olanzapine on the levels of blood lipids and cholesterol in healthy subjects of different TCF7L2 genotypes. We sought to determine whether acute olanzapine treatment caused any changes in the levels of blood lipids and cholesterol in healthy subjects with or without TCF7L2 rs7903146. 4A and table 2 ). There was no significant difference in the baseline level of HDL-cholesterol between CC and CT subjects. As such, after olanzapine treatment, there was a trend that CC subjects had a higher level of HDL-cholesterol than CT subjects (CC versus CT, difference À4.88 [À10.1 to 0.345] mg/dL, p = 0.065) (table 2). However, the interaction between the effects by genotype and by olanzapine treatment on HDL-cholesterol level was not significant. We did not find any effects by either rs7903146 or olanzapine treatment on the plasma level of total cholesterol (TC) and low-density lipoprotein cholesterol (LDL-cholesterol) in the healthy subjects (table 2) .
Effects of olanzapine on the plasma levels of uric acid in healthy subjects. We determined the plasma levels of uric acid in healthy subjects with different TCF7L2 genotypes. The three doses of acute olanzapine treatment caused significant changes on uric acid level in plasma (olanzapine: no versus yes, difference 0.87 [0.388-1.36] mg/dL, p = 0.002) ( fig. 4B and table 2) . This alteration by olanzapine seems not to be associated with TCF7L2 genotype at the locus of rs7903146.
Plasma concentrations of olanzapine in healthy subjects of different TCF7L2 genotypes. To ascertain whether any metabolic change by TCF7L2 rs7903146 was via its effect on the pharmacokinetics of olanzapine, we determined the plasma concentrations of olanzapine using the blood samples collected during OGTT after olanzapine treatment. There were no statistical differences in the plasma concentrations of olanzapine between the two TCF7L2 genotypes (CC versus CT) ( fig. S1 ). Calculated from these plasma concentrations, the AUC during OGTT showed no difference between the two genotypes (data not shown). We also did a correlation analysis, but did not find any correlation between the metabolic changes and the olanzapine concentration.
Discussion
In this study, we have demonstrated that olanzapine treatment causes rapid metabolic effects that are measurable as early as in the fourth day of treatment. These metabolic effects include increased body-weight, an elevated level of triglyceride and a decreased level of HDL-cholesterol. Moreover, we found that the levels of certain basal metabolic indicators and metabolic responses to olanzapine treatment are associated with TCF7L2 rs7903146 in healthy subjects. To our knowledge, this is the first prospective attempt to investigate the association between the common diabetic risk polymorphism (rs7903146) in TCF7L2 gene and the rapid metabolic effects of olanzapine in human subjects.
Human TCF7L2 genetic polymorphism such as rs7903146, which has been associated with increased TCF7L2 expression in the pancreas, confers the strongest genetic risk to glucose intolerance and T2D in populations [24, 25] . Insulin-secreting islets in the pancreas play a critical role in the maintenance of metabolic homeostasis. It has previously been reported that TCF7L2 rs7903146 is associated with higher insulin secretion in humans [26] . We and others have shown that global reduction in Tcf7 l2 expression confers decreased metabolic risk in mice [27] . Contradictorily, Le Bacquer et al. [28] recently found that rs7903146 was associated with reduced basal and glucose-stimulated islet insulin secretion, although the high frequency of other TCF7L2 polymorphic alleles and the disease conditions of the subjects in this study may complicate the phenotypes. In the current study, the young healthy Chinese subjects with rs7903146 showed overall significantly higher insulin levels during OGTT at baseline and after olanzapine administration. The effect size by rs7903146 in our healthy subjects seems to be not large, as only a trend but insignificant difference of insulin level was observed at the time-points of 0.5 and 1 hr during OGTT. Increased TCF7L2 expression has been detected in T2D donors, in particular those with rs7903146 [29] [30] [31] . While the molecular mechanism for the impact of rs7903146 on insulin secretion remains to be characterized, it is plausible that the polymorphism causes increased insulin secretion, and when combined with certain chronic stresses on b cells, may speed up their failure and eventually lead to insufficient function. Chronic olanzapine treatment causes insulin resistance in patients [32] . The findings from a previous study with a small sample size indicated that 8 or 10 days of olanzapine administration decreased insulin sensitivity in healthy males [33, 34] . However, contradictory findings were reported as Sowell et al. found no alteration in insulin sensitivity after three weeks of olanzapine treatment [35] . More recently, Albaugl et al. showed that a 3-day course of olanzapine treatment had no effect on glucose AUC during OGTT [36] . In the current study, we failed to observe any effect of olanzapine on glucose and insulin levels during OGTT following 4 doses of olanzapine administration in each TCF7L2 rs7903146 genotype. We then calculated the insulin sensitivity index (ISI) as the 10,000/square root of ([fasting glucose (mg/dL) 9 fasting insulin (lIU/mL)] 9 [mean glucose (mg/dL) 9 mean insulin (lIU/mL) during OGTT]) and the homeostatic model assessment of insulin resistance (HOMA-IR) as fasting plasma insulin (lIU/mL) 9 fasting plasma glucose (mmol/L)/22.5 [37] . Similarly, the olanzapine treatment in this study did not have any significant impact on ISI and HOMA-IR either. While it is likely that the term of 3-day olanzapine treatment is too short to cause any detectable change in insulin sensitivity, our data suggest that acute olanzapine treatment with clinically relevant doses has no apparent effect on glucose metabolism and insulin secretion.
The most commonly reported side effect of AAPs, and particularly of olanzapine and clozapine, is body-weight gain that is a major reason for patient non-compliance [38, 39] . Weight gain causes insulin resistance and, as a result, other components of the metabolic syndromes. It has been reported that administration of olanzapine for 1 week led to a three time increase in body-weight gain and a 35% increase in fat deposits compared to controls in a rat model [40] . Patients with schizophrenia usually gain weight after a short time on AAPs [41] , and long-term treatment induces weight gains of at least 5 kg in up to 50% of patients [42] . While we did not observe any difference in basal body-weight and BMI between healthy subjects bearing an rs7903146 risk allele T and those bearing only reference allele C, to our surprise, only three days of olanzapine treatment caused a significant weight gain in the subjects. Notably, a recent study by Vance et al. [36] reported no body-weight gain by three days of olanzapine treatment in healthy subjects, which may be ascribed to various characteristics of the subjects. The ethnic background and TCF7L2 polymorphism of their subjects are unknown, and both genders are included. A number of studies have reported that gender has an impact on the nature of and susceptibility to the side effects of AAPs in clinical trials and animal models [43] . In the current study, the weighing scale had been carefully calibrated timely and the timing of the measurement was the same at 7:00 AM after overnight fasting during the study. However, we would like to point out that our clinical study design was not cross-over with placebo-control and a period effect on weight gain could not be fully excluded. Clearly, future studies are needed to validate this interesting finding on the bodyweight gain due to acute olanzapine treatment.
Large public health studies have demonstrated that cardiovascular disease (CVD) is the single largest cause of death in patients with schizophrenia [44, 45] . The use of AAPs such as olanzapine may cause dyslipidaemia, which is one of the major causes of CVD and of mortality in patients with mental illness [46, 47] . In the present study, acute olanzapine treatment significantly increased the plasma triglycerides level in both the subjects with rs7903146 and those without. Moreover, there is an interaction between the effects by rs7903146 and by olanzapine treatment on the triglyceride level. It is interesting to note that while rs7903146 is a genetic risk factor for T2D, the healthy subjects bearing this SNP had a lower plasma triglycerides level. This is consistent with a previous report of lower levels of triglycerides in newly diagnosed T2D patients with rs7903146 [48] . Chronic olanzapine treatment has been associated with increased total and LDLcholesterol as well as deceased HDL-cholesterol levels [49] . In the present study, the 3-day olanzapine treatment could cause significant decline in the plasma HDL-cholesterol level without detectable changes in the total and LDL-cholesterol, the level of which is mainly associated with the risk of CVD. Although the data imply an acute adverse effect by olanzapine on cholesterol or the lipid profile, the effect is small. However, the effect seemed to be larger in the subjects with TCF7L2 rs7903146 T allele. Further studies are needed to determine whether TCF7L2 polymorphism has any effect on blood lipid levels in the clinical patients receiving chronic olanzapine treatment.
Several previous studies have reported that serum uric acid concentration is associated with a variety of metabolic disorders including diabetes [50] , insulin resistance [51] , obesity and metabolic syndrome [52, 53] . Hyperuricemia can also predict subsequent weight gain and blood pressure elevation. Recently, Weghuber and colleagues have reported that serum uric acid is a reliable predictor of metabolic syndrome in overweight or obese subjects and proposed that the uric acid level is a possible biomarker of future metabolically adverse status prior to fulfilling the metabolic syndrome criteria [54] . The underlying mechanism behind this association between increased uric acid and the risk of metabolic disorders is not clear, but may occur in the kidney [52] . In the current study, the uric acid level was significantly increased by olanzapine treatment from 5.68 mg/dL to 6.56 mg/dL in the subjects. Interestingly, the uric acid level in the healthy subjects bearing an rs7903146 risk T allele tends to be higher than those bearing only reference C allele whether before or after olanzapine treatment. Whether the increase in uric acid is an early biomarker of adverse metabolic effects associated with olanzapine treatment needs future longitudinal research among patients undergoing olanzapine treatment.
Besides those indicators related to the metabolism of glucose and lipids that intriguingly found to be altered by acute olanzapine treatment, we also observed that total protein, albumin and haemoglobin in the blood were significantly decreased by the three-day course of olanzapine treatment in the healthy subjects. In contrast, long-term clinical use of olanzapine is associated with elevated levels of haemoglobin in patients [55] , which may be secondary to the metabolic changes such as body-weight gain by the drug. The underlying mechanism for the change in proteins levels by acute olanzapine treatment is not clear. It may be related to acute functional changes in the liver where albumin and haemoglobin are synthesized. The results from other clinical trials have indicated that chronic olanzapine treatment may lead to hepatic function changes in adolescent patients [56] .
There are limitations in the present study. Those patients therapeutically treated by olanzapine are under long-term use in the clinic. Although our findings could benefit the mechanistic understanding of adverse metabolic effects from olanzapine use, the current study with acute olanzapine treatment may not be reflective of clinical changes in patients. Moreover, we employed a relatively simple open-label design in this genotype-phenotype association study. However, a crossover design with placebo-control would result in more reliable conclusions on the effect of acute olanzapine treatment on body-weight gain. In addition, we performed multiple analyses on our small sample size of subjects. There is a fair risk of false-positive results (type 1 error). Considering these limitations, verification of our findings in large-scale, well-designed studies in patient populations is warranted.
In conclusion, the present study has demonstrated that short-term olanzapine treatment can cause rapid metabolic changes in healthy human beings. Our findings suggest a role of the TCF7L2 rs7903146 polymorphism in metabolic homeostasis and olanzapine-induced metabolic changes in healthy human beings.
